Gastrointestinal Stromal Tumour (GIST)
Gastrointestinal stromal tumour commonly shortened to GIST is a rare type of cancer that develops in the wall of the digestive tract. It arises from specialised cells called the interstitial cells of Cajal, which normally control muscle contractions that move food through the gut. GIST can occur anywhere along the digestive tract, though the stomach and small intestine are affected most often. Unlike more common gastrointestinal cancers GIST does not begin in the glandular lining but in the connective and muscular tissue beneath it. Tumours range widely in size and behaviour, from small growths discovered incidentally to large masses causing significant symptoms. Most cases result from a specific gene mutation and this genetic basis now shapes both diagnosis and treatment.
Types of Gastrointestinal Stromal Tumour (GIST)
GIST is classified according to its location within the digestive tract. Different types are:
- Gastric GIST: The most common form, accounting for around 60% of cases, arising in the stomach wall.
- Small intestinal GIST: Develops in the jejunum or ileum and tends to behave more aggressively than gastric tumours.
- Rectal & colonic GIST: Less common than other types, these tumours occur near the anal canal and because of their location, can lead to bleeding or bowel obstruction as they grow.
- Oesophageal GIST: They are rare tumours and often present with swallowing difficulty.
- Extra-gastrointestinal GIST: Arises outside the digestive tract itself most often in the abdominal cavity or peritoneum.
Causes of Gastrointestinal Stromal Tumour
GIST develops when specific genetic mutations cause interstitial cells of Cajal to grow and divide uncontrollably. These include:
- The KIT gene mutation is present in the majority of cases; it triggers continuous activation of cell growth signals.
- PDGFRA gene mutations account for a smaller proportion of tumours and often respond differently to targeted drugs.
- A minority of tumours carry neither KIT nor PDGFRA mutations and are described as wild-type GIST.
- Neurofibromatosis type 1, an inherited condition, increases the risk of developing GIST particularly in the small intestine.
- Because Carney triad and Carney-Stratakis syndrome are rare hereditary conditions, they are linked to multiple GISTs occurring together.
- Some cases arise sporadically without any identifiable inherited cause or family history.
Signs & Symptoms of Gastrointestinal Stromal Tumour
Many small GISTs cause no symptoms at all and are found incidentally during scans or endoscopy for unrelated reasons. When symptoms develop they can be:
- Abdominal pain or discomfort often develops as the tumour grows large enough to press on surrounding structures.
- Gastrointestinal bleeding appearing as dark stools or vomited blood is a common presenting sign.
- A palpable abdominal mass may be noticed by the patient or found during a routine physical examination.
- Because chronic blood loss can occur silently, unexplained fatigue and anaemia sometimes appear before any pain does.
- Early satiety and a persistent feeling of fullness after small meals can indicate a tumour pressing on the stomach.
- Nausea and vomiting develop when a tumour partially obstructs the passage of food through the gut.
Risk Factors of Gastrointestinal Stromal Tumour
Unlike many cancers, GIST is not strongly linked to lifestyle factors such as smoking or diet and its risk profile is largely genetic.
- Age between 50 and 70 - most cases are diagnosed within this range, though GIST can occur at any age.
- A diagnosis of neurofibromatosis type 1 significantly raises the lifetime risk of developing GIST.
- Family history of Carney-Stratakis syndrome increases the chance of multiple tumours forming over time.
- Slightly more men than women are affected, though the difference is modest.
Complications of Gastrointestinal Stromal Tumour
Complications from GIST usually relate to the tumour's size, location and tendency to bleed or spread. Common complications are:
- Tumours that erode through the gut lining can cause sudden or gradual internal bleeding.
- Bowel obstruction can occur when a tumour grows large enough to block the passage of food or stool.
- Tumour rupture (rare) is a serious event that can lead to bleeding within the abdominal cavity.
- It can spread to liver and the peritoneal lining.
- Resistance to targeted drug therapy can develop over time, complicating long-term disease control.
Diagnosis
Diagnosis of GIST involves imaging to locate the tumour and biopsy to confirm its cellular origin. Investigations are:
- Endoscopy or endoscopic ultrasound allows direct visualisation of the tumour and guided biopsy sampling.
- CT and MRI scans assess tumour size, location and whether the disease has spread to other organs.
- A biopsy involves examining tissue under a microscope to confirm the diagnosis.
- Immunohistochemistry testing for CD117 and DOG1 markers helps distinguish GIST from other gastrointestinal tumours.
- Because treatment choice depends on the underlying mutation, genetic testing for KIT and PDGFRA is routinely performed.
- PET scans are sometimes used to monitor how well a tumour is responding to treatment.
Treatment of Gastrointestinal Stromal Tumour
Treatment for GIST depends on tumour size, location and mutation status and often combines surgery with targeted drug therapy.
- Watchful waiting: For very small, low-risk GISTs that aren't causing symptoms doctors sometimes recommend regular monitoring instead of immediate treatment. This usually involves periodic imaging scans to track the tumour's size and behaviour.
- Surgical intervention: Removing the tumour completely along with a margin of surrounding healthy tissue is the treatment of choice for localised GIST. For smaller tumours, this alone can sometimes cure the disease completely.
- Targeted therapy: Most GISTs carry a genetic mutation that causes their growth and targeted drugs work by blocking the specific signal fuelling that growth. These medications are used before surgery to shrink large tumours or after surgery to lower the chance of the cancer coming back.
- Advanced or metastatic GIST: When GIST has spread beyond its original site targeted drug therapy becomes the primary treatment rather than surgery. If the first drug stops working over time, doctors can switch to other targeted medications tailored to overcome that resistance and keep the tumour under control.
- Adjuvant therapy given after surgery reduces the chance of recurrence in tumours judged to carry higher risk.
When to See a Doctor
Persistent digestive symptoms without an obvious cause should warrant a medical assessment. They are:
- Ongoing or worsening abdominal pain that does not settle within a couple of weeks
- Dark, tarry stools or vomiting blood
- A noticeable abdominal lump or swelling
- Unexplained fatigue
- Anyone with neurofibromatosis type 1 or a family history of Carney-Stratakis syndrome should discuss appropriate screening with their doctor.
Conclusion
GIST is an uncommon cancer that arises from the connective tissue of the digestive tract and in most cases it is caused by a specific genetic mutation. Catching it early through prompt evaluation of any suspicious symptoms widens the range of treatment options available and generally leads to better outcomes. Over the past few decades, targeted drug therapy has transformed the outlook for GIST patients, turning what was once a difficult-to-treat cancer into one that can often be managed effectively. For most patients surgery combined with targeted therapy is the backbone of treatment. Because recurrence is always a possibility even after successful treatment, regular follow-up and ongoing monitoring afterwards are strongly advised to catch any signs early.
FAQs
1. Is GIST a type of cancer?
Yes, GIST is a rare type of cancer that develops in the connective tissue of the digestive tract wall.
2. What tests are used to diagnose GIST?
Diagnosis typically involves endoscopy, CT or MRI imaging and a biopsy tested for CD117 and DOG1 markers.
3. Can GIST spread to other parts of the body?
If left untreated, GIST can spread most commonly to the liver or the lining of the abdominal cavity.
4. Can GIST come back after treatment?
GIST can recur after treatment, which is why regular follow-up imaging is recommended even after successful surgery.
5. How often does a patient with GIST need follow-up?
Follow-up frequency varies by risk level, but most patients undergo imaging every three to six months in the years after treatment.
+91 406 810 6585
